Updated mRNA-1273 vaccine was effective against severe COVID-19 outcomes in older and high-risk adults during the 2024-2025 season.
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
In a phase 3 clinical trial, the tetravalent dengue vaccine, developed by the Butantan Institute in São Paulo, Brazil, was 80.5% effective against severe dengue cases with warning signs over a ...
mRNA-1345, a lipid nanoparticle encapsulated messenger RNA (mRNA)-based vaccine, was well tolerated and immunogenic in solid organ transplant recipients, inducing neutralizing antibodies against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results